- Home
- ACRS vs CABA Comparison
ACRS vs CABA Comparison
Compare ACRS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- CABA
- Stock Information
- Founded
- ACRS 2012
- CABA 2017
- Country
- ACRS United States
- CABA United States
- Employees
- ACRS N/A
- CABA N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACRS Health Care
- CABA Health Care
- Exchange
- ACRS Nasdaq
- CABA Nasdaq
- Market Cap
- ACRS 230.8M
- CABA 200.2M
- IPO Year
- ACRS 2015
- CABA 2019
- Fundamental
- Price
- ACRS $2.85
- CABA $2.40
- Analyst Decision
- ACRS Strong Buy
- CABA Strong Buy
- Analyst Count
- ACRS 5
- CABA 8
- Target Price
- ACRS $9.75
- CABA $13.50
- AVG Volume (30 Days)
- ACRS 1.4M
- CABA 5.2M
- Earning Date
- ACRS 11-06-2025
- CABA 11-10-2025
- Dividend Yield
- ACRS N/A
- CABA N/A
- EPS Growth
- ACRS N/A
- CABA N/A
- EPS
- ACRS N/A
- CABA N/A
- Revenue
- ACRS $15,742,000.00
- CABA N/A
- Revenue This Year
- ACRS N/A
- CABA N/A
- Revenue Next Year
- ACRS N/A
- CABA N/A
- P/E Ratio
- ACRS N/A
- CABA N/A
- Revenue Growth
- ACRS N/A
- CABA N/A
- 52 Week Low
- ACRS $1.05
- CABA $0.99
- 52 Week High
- ACRS $4.24
- CABA $5.46
- Technical
- Relative Strength Index (RSI)
- ACRS 67.71
- CABA 49.12
- Support Level
- ACRS $2.34
- CABA $2.01
- Resistance Level
- ACRS $2.57
- CABA $2.31
- Average True Range (ATR)
- ACRS 0.22
- CABA 0.22
- MACD
- ACRS 0.03
- CABA -0.03
- Stochastic Oscillator
- ACRS 96.18
- CABA 55.40
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.